Vertex Pharmaceuticals Incorporated

NEW YORK (Reuters) - Vertex Pharmaceuticals Inc said its experimental oral drug for rheumatoid arthritis met the main goals of a mid-stage study. Vertex's VX-509 significantly reduced signs and symptoms of the painful condition and disease activity at the two highest of four tested doses compared with a placebo after 12 weeks of treatment, according to results of the 204-patient mid-stage trial released on Tuesday. The company, which in May launched its first commercial product -- the hepatitis C treatment Incivek -- plans to evaluate VX-509 in a six-month mid-stage study based on results of the 12-week trial. VX-509 targets a protein known as JAK3, which has been a hot area of...

Related "Vertex Pharmaceuticals Incorporated" Articles

NEW YORK (Reuters) - Vertex Pharmaceuticals Inc said its experimental oral drug for rheumatoid arthritis met the main goals of a mid-stage study.
Vertex's VX-509 significantly reduced signs and symptoms of the painful condition and disease activity at...

(Reuters) - Pharmasset Inc said its hepatitis C shot showed positive results in a trial involving patients who have not been previously treated for the infection, sending its shares to a life-high on Tuesday morning.
In a mid-stage trial named PROTON, 98...